Addex Therapeutics

Ein Kommentar / 0 new
Bild des Benutzers robincould
Zuletzt online: 08.11.2018
Mitglied seit: 21.11.2011
Kommentare: 603
Addex Therapeutics

an Leeuwenhoeck Issues Research Note on Addex Therapeutics

Geneva, Switzerland, 8 June 2016 – Addex Therapeutics (SIX: ADXN), announced today that the independent life science research company Van Leeuwenhoeck has issued a research report on Addex Therapeutics. The research report estimates a current “risk-adjusted NPV (net present value) of CHF 6.5 per share” (ADXN closing price 7 June: CHF2.32).

“We see substantial upside potential in the Addex share price from the current level.” commented Marcel Wijma, Chief Research Analyst at Van Leeuwenhoeck Institute “Addex has a substantial portfolio of clinical and late preclinical programs including a Phase III ready asset in a disease area with a market potential in the US alone of more than USD 2 billion.”

The full analyst research report is available on and on Addex website at under Investors/downloads/analyst reports.